Insmed Growth Treatment iPlex Enters Market
This article was originally published in The Pink Sheet Daily
Executive Summary
Mecasermin rinfabate injection will compete with Tercica’s Increlex.
You may also be interested in...
Expanded Access Program For Insmed’s Iplex Shows Power Of Patient Advocates At FDA
Lou Gehrig’s patients who appealed to the agency early will get access to drug; others enter a lottery system as part of a clinical trial.
Expanded Access Program For Insmed’s Iplex Shows Power Of Patient Advocates At FDA
Lou Gehrig’s patients who appealed to the agency early will get access to drug; others enter a lottery system as part of a clinical trial.
Tercica Will Transition Patients On iPlex To Increlex Following Insmed Patent Settlement
Insmed will no longer provide iPlex growth hormone to short stature patients but can pursue development of the drug in certain other indications.